Results 311 to 320 of about 755,388 (347)
Some of the next articles are maybe not open access.
Radiologic Clinics of North America, 2007
Imaging has become an essential part of the clinical management of patients with ovarian cancer, contributing to tumor detection, characterization, staging, treatment planning, and follow-up. Imaging findings incorporated into the clinical impression assist in creating a treatment plan specific for an individual patient.
Svetlana, Mironov +3 more
openaire +2 more sources
Imaging has become an essential part of the clinical management of patients with ovarian cancer, contributing to tumor detection, characterization, staging, treatment planning, and follow-up. Imaging findings incorporated into the clinical impression assist in creating a treatment plan specific for an individual patient.
Svetlana, Mironov +3 more
openaire +2 more sources
Critical Reviews in Oncology/Hematology, 2006
Ovarian cancer accounts for 4% of all cancers in women and is the leading cause of death from gynaecologic malignancies. Because early-stage ovarian cancer is generally asymptomatic, approximately 75% of women present with advanced disease at diagnosis. Survival is highly dependent on stage of disease: 5-year survival in patients with early-stage is 80-
COLOMBO, NICOLETTA +6 more
openaire +2 more sources
Ovarian cancer accounts for 4% of all cancers in women and is the leading cause of death from gynaecologic malignancies. Because early-stage ovarian cancer is generally asymptomatic, approximately 75% of women present with advanced disease at diagnosis. Survival is highly dependent on stage of disease: 5-year survival in patients with early-stage is 80-
COLOMBO, NICOLETTA +6 more
openaire +2 more sources
Journal of Reproductive Immunology, 1998
Previous observations from our laboratory have demonstrated that the levels of immunoreactive inhibin (ir-inh) are elevated in almost all patients with granulosa cell tumors and in the majority of postmenopausal women with mucinous ovarian cancers.
H G, Burger +13 more
openaire +3 more sources
Previous observations from our laboratory have demonstrated that the levels of immunoreactive inhibin (ir-inh) are elevated in almost all patients with granulosa cell tumors and in the majority of postmenopausal women with mucinous ovarian cancers.
H G, Burger +13 more
openaire +3 more sources
Seminars in Oncology Nursing, 2002
To review the progress in the management of ovarian cancer in the last decade and future directions.Research studies, review articles, and abstracts.There is an increased understanding of ovarian cancer biology, the genetic basis for hereditary ovarian cancer, staging and the role of cytoreductive surgery, and more effective chemotherapy, resulting in ...
openaire +2 more sources
To review the progress in the management of ovarian cancer in the last decade and future directions.Research studies, review articles, and abstracts.There is an increased understanding of ovarian cancer biology, the genetic basis for hereditary ovarian cancer, staging and the role of cytoreductive surgery, and more effective chemotherapy, resulting in ...
openaire +2 more sources
Nursing
Abstract: Ovarian cancer, a leading cause of cancer deaths, poses challenges due to insidious development and vague signs and symptoms. Risk factors include age, reproductive history, genetic mutations, and environmental factors. Treatment involves surgery, chemotherapy, and targeted therapy, with nursing interventions focusing on symptom ...
Caruso, Giuseppe +2 more
openaire +3 more sources
Abstract: Ovarian cancer, a leading cause of cancer deaths, poses challenges due to insidious development and vague signs and symptoms. Risk factors include age, reproductive history, genetic mutations, and environmental factors. Treatment involves surgery, chemotherapy, and targeted therapy, with nursing interventions focusing on symptom ...
Caruso, Giuseppe +2 more
openaire +3 more sources
Seminars in Oncology, 2001
Newer agents and combinations are needed in order to improve current results in the treatment of ovarian cancer. Gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN) is a novel agent with a unique mechanism of action that has shown consistent activity as a single-agent in platinum-resistant ovarian cancer, with remission rates of nearly 20 ...
M, Orlando, M, Mandachain
openaire +2 more sources
Newer agents and combinations are needed in order to improve current results in the treatment of ovarian cancer. Gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN) is a novel agent with a unique mechanism of action that has shown consistent activity as a single-agent in platinum-resistant ovarian cancer, with remission rates of nearly 20 ...
M, Orlando, M, Mandachain
openaire +2 more sources
Obstetrics & Gynecology, 2001
To examine the symptoms of ovarian cancer in patients compared with symptoms experienced by healthy women using a case-control design.Cases (n = 168) were women with ovarian cancer diagnosed at two hospitals in New York between 1994 and 1997 who were interviewed shortly after diagnosis.
S H, Olson +5 more
openaire +2 more sources
To examine the symptoms of ovarian cancer in patients compared with symptoms experienced by healthy women using a case-control design.Cases (n = 168) were women with ovarian cancer diagnosed at two hospitals in New York between 1994 and 1997 who were interviewed shortly after diagnosis.
S H, Olson +5 more
openaire +2 more sources
Pathogenesis of Ovarian Cancers
Journal of the Society for Gynecologic Investigation, 1994To review our current understanding of the molecular genetic events involved in the development of epithelial ovarian cancers.Molecular biologic techniques have been used to examine the role of growth-stimulatory genes (oncogenes) and -inhibitory genes (tumor suppressors) in ovarian cancer.A number of different peptide growth factors and their ...
A, Berchuck +4 more
openaire +2 more sources
International Journal of Gynecological Cancer, 2008
Mucinous epithelial ovarian cancer (mEOC) accounts for approximately 10% of EOCs. Patients presenting with early-stage disease have an excellent prognosis, however, those with advanced disease have a poor outcome with relative resistance to standard ovarian cancer chemotherapy.
M L, Harrison, C, Jameson, M E, Gore
openaire +2 more sources
Mucinous epithelial ovarian cancer (mEOC) accounts for approximately 10% of EOCs. Patients presenting with early-stage disease have an excellent prognosis, however, those with advanced disease have a poor outcome with relative resistance to standard ovarian cancer chemotherapy.
M L, Harrison, C, Jameson, M E, Gore
openaire +2 more sources
Acta Obstetricia et Gynecologica Scandinavica, 1992
Tumorigenesis is a multistep process involving mutations of dominantly acting proto‐oncogenes and mutations and loss‐of‐function mutations of tumor suppressor genes. Some of these mutations may be inherited, but most of them are acquired. Models for the sequential steps of the genetic changes involved in tumor development have been proposed for certain
openaire +2 more sources
Tumorigenesis is a multistep process involving mutations of dominantly acting proto‐oncogenes and mutations and loss‐of‐function mutations of tumor suppressor genes. Some of these mutations may be inherited, but most of them are acquired. Models for the sequential steps of the genetic changes involved in tumor development have been proposed for certain
openaire +2 more sources